Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Discontinuing maintenance therapy in multiple myeloma based on ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Minimal residual disease (MRD) ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

New data have come forward pointing to a link between achieving undetectable minimal residual disease (MRD) and improved treatment outcomes in multiple myeloma. The FDA appears receptive to the idea ...

Myriad Genetics, Inc. MYGN recently announced a research collaboration with Memorial Sloan Kettering Cancer Center (“MSK”). The partnership will study the use of minimal residual disease (MRD) testing ...

Over the past decade, minimal residual disease (MRD) has emerged as a crucial biomarker in multiple myeloma (MM) clinical trials, with MRD-negative status strongly linked to better clinical responses ...

“Relative to many other cancer types that typically have high levels of ctDNA in the blood, breast cancer often has very low levels of ctDNA, which makes MRD testing a challenge,” said Dale Muzzey, ...

Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop ...